Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) – Company response

Pursuant to Rule 12d1-2 promulgated under the Securities Exchange Act of 1934, as amended, Clinuvel Pharmaceuticals Limited (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form 20-F (File No. 001-43353) to become effective at 4:00 p.m. Eastern time on July 17, 2024, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request by telephone call to the staff of the Commission.